Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy

REFERENCES

1. 1.↵
   1. Hughes M,
   2. Allanore Y,
   3. Chung L,
   4. Pauling JD,
   5. Denton CP,
   6. Matucci-Cerinic M.

   Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2020;16:208-21.

   OpenUrlPubMed
2. 2.↵
   1. Kowal-Bielecka O,
   2. Fransen J,
   3. Avouac J, et al; EUSTAR Coauthors

   . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327-39.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Sitbon O,
   2. Channick R,
   3. Chin KM, et al; GRIPHON Investigators

   . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522-33.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Gaine S,
   2. Chin K,
   3. Coghlan G et al.

   Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J 2017;50:1602493.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Di Battista M,
   2. Della Rossa A,
   3. Da Rio M,
   4. De Mattia G,
   5. Morganti R,
   6. Mosca M.

   Preliminary clinical and laser speckle contrast analysis data on selexipag efficacy for the treatment of digital vasculopathy in systemic sclerosis. J Rheumatol 2023;50:1029-31.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Khanna D,
   2. Furst DE,
   3. Clements PJ, et al.

   Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017;2:11-8.

   OpenUrlPubMed
7. 7.↵
   1. Cutolo M,
   2. Sulli A,
   3. Pizzorni C,
   4. Accardo S.

   Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.

   OpenUrlPubMed
8. 8.↵
   1. Di Battista M,
   2. Morganti R,
   3. Tani E,
   4. Da Rio M,
   5. Della Rossa A,
   6. Mosca M.

   Definition and application of proximal-distal gradient finger perfusion in systemic sclerosis by laser speckle contrast analysis. Microvasc Res 2022;140:104307.

   OpenUrl
9. 9.↵
   1. Ingegnoli F,
   2. Schioppo T,
   3. Allanore Y, et al.

   Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum 2019;48:686-93.

   OpenUrl
10. 10.↵
    1. Denton CP,
    2. Hachulla É,
    3. Riemekasten G, et al; Raynaud Study Investigators

    . Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol 2017;69:2370-9.

    OpenUrl
11. 11.↵
    1. Scorza R,
    2. Caronni M,
    3. Mascagni B, et al.

    Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19:503-8.

    OpenUrlPubMed
12. 12.↵
    1. Bettoni L,
    2. Geri A,
    3. Airò P, et al.

    Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002;21:244-50.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Tiev KP,
    2. Diot E,
    3. Clerson P, et al.

    Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 2009;36:1470-6.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Coelho Horimoto AM,
    2. de Souza AS,
    3. Rodrigues SH,
    4. Kayser C.

    Risk of digital ulcers occurrence in systemic sclerosis: a cross-sectional study. Adv Rheumatol 2019;59:14.

    OpenUrl
15. 15.↵
    1. Galiè N,
    2. Gaine S,
    3. Channick R, et al.

    Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension. Adv Ther 2022;39:796-810.

    OpenUrl
16. 16.↵
    1. McLaughlin V,
    2. Farber HW,
    3. Highland KB, et al.

    Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant 2024;43:272-83.

    OpenUrl
17. 17.↵
    1. Merkel PA,
    2. Herlyn K,
    3. Martin RW, et al; Scleroderma Clinical Trials Consortium

    . Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;46:2410-20.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Cutolo M,
    2. Vanhaecke A,
    3. Ruaro B, et al; EULAR Study Group on Microcirculation in Rheumatic Diseases

    . Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients. Autoimmun Rev 2018;17:775-80.

    OpenUrl